Drugs / BAX326
BAX326
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01488994 | Dec 2011 → May 2013 | hemophilia B | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01174446 | Jul 2010 → May 2012 | hemophilia B | Baxalta now part of Shire | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAX326 | “BAX326 is a recombinant factor IX (rFIX; nonacog gamma) manufactured without the addition of any materials of human or animal origin” PMID 23834666 ↗ Jul 2013 |
| Known as | nonacog gamma | “BAX326 is a recombinant factor IX (rFIX; nonacog gamma) manufactured without the addition of any materials of human or animal origin” PMID 23834666 ↗ Jul 2013 |
| Known as | recombinant Factor IX | “All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50...” NCT01488994 ↗ |
| Modality | Protein / enzyme biologic | “BAX326 is a recombinant factor IX (rFIX; nonacog gamma)” PMID 23834666 ↗ Jul 2013 |